Chemo-free triplet aims to outsmart incurable lymphoma

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Willing to participate in the clinical study and signed informed consent. 2. Age ≥18 years, no gender restrictions. 3. Pathologically diagnosed with follicular lymphoma (Grade 1, 2, or 3a) and previously untreated. 4. Has at least one measurable or assessable lesion. 5. Ann-Arbor stage III or IV, or stage II with bulky disease. 6. Meets at least one GELF criterion. 7. Eastern Cooperative Oncology Group (ECOG) performance status score ≤2. 8. Adequate major organ function. Exclusion Criteria: 1. Known active central nervous system lymphoma or leptomeningeal disease. 2. Evidence of follicular lymphoma with transformation to diffuse large B-cell lymphoma. 3. Prior history of other malignancies other than follicular lymphoma (except for those with disease-free survival ≥5 years and assessed by the investigator as having low risk of recurrence). 4. History of allergy to the investigational drug, similar drugs, or excipients. 5. Known history of human immunodeficiency virus (HIV) infection and/or acquired immunodeficiency syndrome (AIDS). 6. Active systemic infection requiring intravenous antibiotic therapy or hospitalization (occurring within 4 weeks prior to screening). 7. Confirmed progressive multifocal leukoencephalopathy (PML), positive for human T-lymphotropic virus type 1 (HTLV-1), or suspected active/latent tuberculosis. 8. Pregnant or breastfeeding women, and women of childbearing potential who are unwilling to use contraception. 9. Patients with significant dysfunction of vital organs. 10. Receipt of any moderate or strong CYP3A4 inhibitors or strong CYP3A4 inducers within 14 days (or 5 half-lives, whichever is longer) prior to the first dose of sotoclax. 11. Use of strong cytochrome P450 (CYP) 3A4 inhibitors within 7 days prior to the first dose of zanubrutinib, or requirement for continuous use of strong CYP3A inhibitors/inducers. 12. Receipt of concurrent therapy for the study disease outside of this clinical study (including the screening period). 13. Autoimmune anemia and/or thrombocytopenia that does not respond adequately to corticosteroids or other standard treatments. 14. Receipt of medications known to prolong the QT/QTc interval. 15. Vaccination with a live vaccine within ≤35 days prior to the first dose of study drug. 16. Major surgery within 4 weeks prior to the first dose of study drug. 17. Unwillingness or inability to complete all assessments and procedures required by the study.